Access the full text.
Sign up today, get DeepDyve free for 14 days.
E. Cutsem, M. Findlay, B. Osterwalder, W. Kocha, D. Dalley, R. Pazdur, J. Cassidy, L. Dirix, C. Twelves, D. Allman, J. Seitz, J. Schölmerich, H. Burger, J. Verweij (2000)
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 6
C. Twelves, R. Glynne-Jones, J. Cassidy, J. Schüller, Timothy Goggin, B. Roos, L. Banken, M. Utoh, E. Weidekamm, B. Reigner (1999)
Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites.Clinical cancer research : an official journal of the American Association for Cancer Research, 5 7
M. Mackean, A. Planting, C. Twelves, J. Schellens, D. Allman, B. Osterwalder, B. Reigner, T. Griffin, S. Kaye, J. Verweij (1998)
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 9
B. Reigner, S. Clive, J. Cassidy, D. Jodrell, R. Schulz, Timothy Goggin, L. Banken, B. Roos, M. Utoh, T. Mulligan, E. Weidekamm (1999)
Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patientsCancer Chemotherapy and Pharmacology, 43
E. Cutsem, C. Twelves, J. Cassidy, D. Allman, E. Bajetta, M. Boyer, R. Bugat, M. Findlay, S. Frings, Michaela Jahn, J. Mckendrick, B. Osterwalder, G. Pérez-Manga, R. Rosso, P. Rougier, W. Schmiegel, J. Seitz, P. Thompson, J. Viéitez, C. Weitzel, P. Harper (2001)
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 21
P. Hoff, R. Ansari, G. Batist, J. Cox, W. Kocha, M. Kuperminc, J. Maroun, D. Walde, C. Weaver, Evelyn Harrison, H. Burger, B. Osterwalder, A. Wong, Ralf Wong (2001)
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 8
C. Twelves, E. Cutsem, K. Hieke, C. Barker, C. Jamieson, J. Hornberger, L. Garrison, B. Osterwalder, A. Thibault (1999)
Medical resource use in a phase III trial (SO 14796) of XelodaTM (capecitabine) in previously untreated advanced/metastatic colorectal cancerEuropean Journal of Cancer, 35
N. Shimma, I. Umeda, M. Arasaki, Chikako Murasaki, Masubuchi Kazunao, Y. Kohchi, M. Miwa, M. Ura, N. Sawada, Hitoshi Tahara, I. Kuruma, I. Horii, H. Ishitsuka (2000)
The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine.Bioorganic & medicinal chemistry, 8 7
N. Sawada, T. Ishikawa, F. Sekiguchi, Yutaka Tanaka, H. Ishitsuka (1999)
X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts.Clinical cancer research : an official journal of the American Association for Cancer Research, 5 10
T. Ishikawa, M. Utoh, N. Sawada, Miwa Nishida, Y. Fukase, F. Sekiguchi, H. Ishitsuka (1998)
Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts.Biochemical pharmacology, 55 7
I. Judson, P. Beale, J. Trigo, W. Aherne, T. Crompton, David Jones, E. Bush, B. Reigner (2004)
A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drugInvestigational New Drugs, 17
A. Sobrero, A. Guglielmi, F. Grossi, F. Puglisi, C. Aschele (2000)
Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy.Seminars in oncology, 27 5 Suppl 10
M. Miwa, M. Ura, Miwa Nishida, N. Sawada, T. Ishikawa, K. Mori, N. Shimma, I. Umeda, H. Ishitsuka (1998)
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.European journal of cancer, 34 8
T. Ishikawa, F. Sekiguchi, Y. Fukase, N. Sawada, H. Ishitsuka (1998)
Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts.Cancer research, 58 4
N. Sawada, T. Ishikawa, Y. Fukase, M. Nishida, Takashi Yoshikubo, Hideo Ishitsuka (1998)
Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts.Clinical cancer research : an official journal of the American Association for Cancer Research, 4 4
D. Budman, N. Meropol, B. Reigner, P. Creaven, S. Lichtman, E. Berghorn, J. Behr, R. Gordon, B. Osterwalder, T. Griffin (1998)
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 5
D. Kerr, W. Huinink, J. Bakker, B. Boussard, S. Frings, J. Nortier (2001)
CPT-11 in combination with capecitabine as first line chemotherapy for metastatic colorectal cancer (MCRC): preliminary results of a phase I/II studyEuropean Journal of Cancer, 37
N. Schleucher, M. Tewes, W. Achterrath, Shousong Cao, S. Frings, H. Wilke, A. Harstrick, Y. Rustum, S. Seeber, U. Vanhoefer (2001)
Extended phase I study of capecitabine and weekly irinotecan as first-line chemotherapy in metastatic colorectal cancerEuropean Journal of Cancer, 37
A. Naylor-Olsen, G. Ponticello, S. Lewis, A. Mulichak, Z. Chen, C. Habecker, B. Phillips, W. Sanders, T. Tucker, J. Shafer, J. Vacca (1998)
Identification and SAR for a selective, nonpeptidyl thrombin inhibitor.Bioorganic & medicinal chemistry letters, 8 13
R. Bicknell, A. Harris (1996)
Mechanisms and therapeutic implications of angiogenesis.Current opinion in oncology, 8 1
P. Hoff (2000)
Capecitabine as first-line treatment for colorectal cancer (CRC): integrated results of 1207 patients (pts) from 2 randomized, phase III studies. On behalf of the Capecitabine CRC Study Group [abstract]Ann Oncol, 4
L. Pronk, P. Vasey, A. Sparreboom, B. Reigner, B. Reigner, A. Planting, R. Gordon, R. Gordon, B. Osterwalder, B. Osterwalder, J. Verweij, C. Twelves (2000)
A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumoursBritish Journal of Cancer, 83
Bruno Reigner, J. Verweij, Luc Dirix, J. Cassidy, Chris Twelves, D. Allman, Erhard Weidekamm, B. Roos, Ludger Banken, Masahiro Utoh, B. Osterwalder (1998)
Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.Clinical cancer research : an official journal of the American Association for Cancer Research, 4 4
Capecitabine is an orally administered fluoropyrimidine which is selectively activated in tumor tissue to the active moiety fluorouracil and is cytotoxic through inhibition of DNA synthesis.
American Journal of Cancer – Springer Journals
Published: Aug 9, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.